Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.36 USD
-0.01 (-0.42%)
Updated Oct 14, 2024 03:06 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Armata Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 15 | 10 | 10 | 6 |
Receivables | 3 | 2 | 3 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 10 | 2 | 1 | 1 |
Total Current Assets | 19 | 27 | 15 | 11 | 7 |
Net Property & Equipment | 13 | 4 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 3 | 3 | 3 | 3 |
Deposits & Other Assets | 18 | 19 | 13 | 12 | 11 |
Total Assets | 98 | 96 | 70 | 40 | 25 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 6 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 2 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 3 | 1 |
Total Current Liabilities | 16 | 25 | 5 | 7 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 3 | 3 | 3 | 3 |
Convertible Debt | 59 | 0 | 0 | 0 | 0 |
Long-Term Debt | 24 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 130 | 60 | 44 | 21 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 276 | 275 | 228 | 198 | 172 |
Retained Earnings | -309 | -240 | -203 | -180 | -158 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -32 | 36 | 25 | 19 | 15 |
Total Liabilities & Shareholder's Equity | 98 | 96 | 70 | 40 | 25 |
Total Common Equity | -32 | 36 | 25 | 19 | 15 |
Shares Outstanding | 36.10 | 36.10 | 27.00 | 18.70 | 9.90 |
Book Value Per Share | -0.89 | 1.00 | 0.94 | 1.01 | 1.47 |
Fiscal Year End for Armata Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 26 | 38 | 14 | 24 |
Receivables | NA | 1 | 2 | 3 | 9 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 2 | 2 | 4 |
Total Current Assets | NA | 31 | 42 | 19 | 37 |
Net Property & Equipment | NA | 13 | 13 | 13 | 9 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 3 | 3 | 3 | 3 |
Deposits & Other Assets | NA | 17 | 18 | 18 | 19 |
Total Assets | NA | 108 | 120 | 98 | 113 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 63 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 5 | 6 | 7 |
Current Portion Long-Term Debt | NA | 48 | 97 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 1 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 1 | 0 |
Total Current Liabilities | NA | 123 | 110 | 16 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 3 | 3 | 3 | 3 |
Convertible Debt | NA | 0 | 0 | 59 | 50 |
Long-Term Debt | NA | 0 | 35 | 24 | 22 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 154 | 177 | 130 | 125 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 278 | 277 | 276 | 276 |
Retained Earnings | NA | -325 | -334 | -309 | -289 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -46 | -57 | -32 | -12 |
Total Liabilities & Shareholder's Equity | NA | 108 | 120 | 98 | 113 |
Total Common Equity | 0 | -46 | -57 | -32 | -12 |
Shares Outstanding | 36.10 | 36.10 | 36.10 | 36.10 | 36.10 |
Book Value Per Share | 0.00 | -1.28 | -1.57 | -0.89 | -0.34 |